Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company, announced on Thursday that it has completed enrolment of subjects in a Phase 2b trial of its CRV-101 subunit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults.

The product is a potentially well-tolerated, highly effective shingles vaccine.

The study enrolled 678 participants across eleven US sites, randomised to a high- or low-dose CRV-101 arm or Shingrix. Subjects received two doses, two months apart as is current practice for a shingles vaccine.

The eligibility criteria for enrolling subjects included adults of more than 50 years of age and no prior varicella zoster virus vaccination or history of shingles and were broadly representative of the potential non-immunosuppressed patient population for a shingles vaccine. The study started patient enrolment in February 2022. Topline data from this Phase 2b trial is likely to be revealed in January 2023.